About Kiadis Pharma
Kiadis Pharma is a company based in Amsterdam (Netherlands) founded in 1997 was acquired by Sanofi in November 2020. Kiadis Pharma has raised $32.95 million across 11 funding rounds from investors including Sanofi, Kreos Capital and Life Sciences Partners. Kiadis Pharma has completed 1 acquisition, including Cyto-Sen Therapeutics. Kiadis Pharma operates in a competitive market with competitors including Adicet Bio, Orca Bio, Ossium Health, Rubius Therapeutics and Auron Therapeutics, among others.
- Headquarter Amsterdam, Netherlands
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kiadis Pharma
Kiadis Pharma has successfully raised a total of $32.95M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5.86 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kiadis Pharma
Kiadis Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Sanofi, Kreos Capital and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt is provided to growth-stage companies across multiple sectors.
|
Locked | Locked | Locked | |
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked |
Investor details for Kiadis Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kiadis Pharma
Kiadis Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cyto-Sen Therapeutics.
Investment portfolio details for Kiadis Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
NK cell therapies are developed for acute myeloid leukemia treatment.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Kiadis Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Kiadis Pharma
Detailed financials for Kiadis Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kiadis Pharma Comparisons
Peer comparison for Kiadis Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kiadis Pharma
Kiadis Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, Orca Bio, Ossium Health, Rubius Therapeutics and Auron Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
|
| Locked | Locked | Locked |
Genetically modifying hematopoietic stem cells to create RBC therapeutics in metabolic deficiencies, autoimmune disorders, and cancer
|
|
| Locked | Locked | Locked |
Developer of cancer therapeutics for the treatment of blood cancer
|
|
| Locked | Locked | Locked |
Antibody radionuclide conjugates are developed for haematological cancers.
|
Detailed competitors of Kiadis Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kiadis Pharma
Complete news archive for Kiadis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kiadis Pharma
Kiadis Pharma was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Kiadis Pharma is headquartered in Amsterdam, Netherlands.
Kiadis Pharma is a funded company, having raised a total of $32.95M across 11 funding rounds to date.
Founded in 1997 and based in Amsterdam, Netherlands, Kiadis Pharma operates in the biotechnology sector, focusing on solutions for complications in hematopoietic stem cell transplants for blood cancer patients. Allodepleted T-cell immunotherapeutics (ATIR) are utilized to bolster the patients immune system post-transplant, facilitating acceptance from haploidentical or lower-matched donors. Investigations into ATIR applications for leukemia and thalassemia are ongoing.
Kiadis Pharma's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Kiadis Pharma has made 1 acquisition, including Cyto-Sen Therapeutics.
Kiadis Pharma has 8 investors. Key investors include Sanofi, Kreos Capital, Life Sciences Partners, NVNOM, and Draper Esprit.